clinical trial · NCT05226494
Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma
Glioma, Malignantfb-PMT
brief summary
Glioblastoma is a highly aggressive and fatal form of primary malignant brain tumor with limited treatment options. fb-PMT affects a large group of cancer cell signaling pathways and thus may be effective in heterogeneous, treatment-resistant tumors such as Glioblastoma. fb-PMT also is actively transported across the blood-brain barrier into the brain. This study is being conducted to determine the dose level for further clinical development of fb-PMT to treat recurrent Glioblastoma.
started
Jun 23, 2022
primary completion
Oct 1, 2026
completion
Oct 1, 2027
last updated
Jun 4, 2025
official title
A Phase 1 Trial to Evaluate the Safety and Tolerability of Fb-PMT in Patients With Recurrent Glioblastoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol